T Rowe Price Group Other Income (Expense) decreased by 134.0% to -$48.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 168.3%, from $70.70M to -$48.30M. Over 3 years (FY 2021 to FY 2025), Other Income (Expense) shows an upward trend with a 34.1% CAGR.
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
other_income_expense_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $143.90M | -$11.50M | $50.10M | -$198.50M | -$279.90M | -$82.80M | $135.40M | $106.20M | $2.80M | $259.70M | $188.90M | $80.30M | $212.50M | $4.60M | $70.70M | $235.50M | $238.40M | $142.10M | -$48.30M |
| QoQ Change | — | -108.0% | +535.7% | -496.2% | -41.0% | +70.4% | +263.5% | -21.6% | -97.4% | >999% | -27.3% | -57.5% | +164.6% | -97.8% | >999% | +233.1% | +1.2% | -40.4% | -134.0% |
| YoY Change | — | — | — | — | -294.5% | -620.0% | +168.2% | +137.9% | +103.4% | — | +39.5% | -24.4% | >999% | -98.2% | -62.6% | +193.3% | +12.2% | >999% | -168.3% |